Keros Therapeutics (KROS) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $24.1 million.
- Keros Therapeutics' Total Current Liabilities fell 1694.42% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 1694.42%. This contributed to the annual value of $27.4 million for FY2024, which is 1262.46% up from last year.
- Per Keros Therapeutics' latest filing, its Total Current Liabilities stood at $24.1 million for Q3 2025, which was down 1694.42% from $34.7 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Total Current Liabilities peaked at $39.4 million during Q1 2025, and registered a low of $7.5 million during Q2 2021.
- Its 5-year average for Total Current Liabilities is $19.0 million, with a median of $16.5 million in 2022.
- Examining YoY changes over the last 5 years, Keros Therapeutics' Total Current Liabilities showed a top increase of 11038.04% in 2025 and a maximum decrease of 1694.42% in 2025.
- Keros Therapeutics' Total Current Liabilities (Quarter) stood at $11.8 million in 2021, then soared by 39.68% to $16.5 million in 2022, then skyrocketed by 47.3% to $24.4 million in 2023, then rose by 12.62% to $27.4 million in 2024, then decreased by 12.23% to $24.1 million in 2025.
- Its Total Current Liabilities was $24.1 million in Q3 2025, compared to $34.7 million in Q2 2025 and $39.4 million in Q1 2025.